McMaster University

McMaster University

Monalisa Sur


Pathology and Molecular Medicine

Division: Anatomical Pathology

Associate Member, Department of Oncology


Juravinski Hospital
Room 223
Hamilton, Ontario
905-527-4322 ext. 42051

Dr sur

Faculty Biography

Education and Professional Standing

  • FRCPath (United Kingdom), 2008
  • FRCPC Anatomical Pathology, 2002
  • MRCPath (United Kingdom), 2000
  • MMed (South Africa), 1999
  • FCPath (South Africa), 1998
  • MBBS, Punjab University (India), 1989


Clinical Focus

As an anatomical pathologist, Dr. Sur provides service cover in anatomical pathology for Henderson and Hamilton General Hospitals and the Juravinski Cancer Center.  The service coverage is for surgical cases, cytology and frozen section coverage.  As part of the hematopathology disease site group, Dr. Sur provides cover for hematolpathology cases for HRLMP and provides consultation coverage for Hamilton-Wentworth area hospitals. 

Dr. Sur is also part of the gynaecology-oncology disease site group and provides service and consultation coverage in Gyn-oncology cases for HRLMP and Hamilton-Wentworth area.  She also participates in the multi-disciplinary rounds in both hematopathology and Gyn pathology conducted through the Juravinski Cancer Center. 

Research Focus

Dr. Sur’s research interests are directly integrated with her clinical service component.  Her research interests are in hematopathology and gynaecologic-oncologic pathology.  Her interests in research in these areas range from clinical pathologic correlations and their impact on patient management to identifying prognostic markers in various tumours through ancillary tests such as immunohistochemistry and molecular techniques.

Academic Interests

Dr. Sur is the program director for Anatomical Pathology at McMaster University.  She is chair of the residency program committee of anatomical pathology and chair of the anatomical pathology education committee.  She is member of the CARMs selection committee for the anatomical and general pathology programs and member of the fellowship program selection committee. Dr. Sur is also member and examiner for CEHPEA (Center for the Evaluation of Health Professionals Educated Abroad).  She is actively involved in the undergraduate MD program in unit MF1 and MF4.  As program director of anatomical pathology, she is in charge of maintaining and constantly improving the academic mandate of the anatomical pathology residency program in order to meet and excel the requirements of the Royal College of Physicians and Surgeons of Canada.  Her main areas of interest in teaching covers surgical pathology, hematopathology and gynaecologic pathology.  She supervises and trains residents from within the anatomical and general pathology programs, and also supervises residents from other specialties as well as medical students rotating through pathology. She also acts as supervisor to undergraduate students, particularly in the Life Science and Health Science programs, working on senior projects.  Dr. Sur is currently accepting post-doctorate fellows, post graduate trainees and medical students for electives.  

Team Members

  • Hematology Disease-Site Group
  • Gynaecologic-Oncology Disease-Site GrouP

Selected Publications

  • Misir A, Daya D, Sur M. Cotyledenoid Dissecting Leiomyoma of the Uterus (Sternberg Tumour): A Clinicopathological Study of Six Cases. Canadian Journal of Pathology. 2009; 1(3): 9-15.
  • Sur M, Dhamanaskar P, Misra A, Elavathil L. Lymphomas of the Breast: A Review of 12 years. Canadian Journal of Pathology. 2009;1(4):12-20.
  • Bishara M, Ross C, Sur M. Primary anaplastic large cell lymphoma of the breast arising in reconstruction mammoplasty capsule of the slaine filled breast implant after radical mastectomy for breast cancer: an unusual case presentation Diagnostic Pathology. 2009; 4:11.
  • Hussein S, Sur M. Cytokeratin Positivity in Myxopapillary Ependymoma- a potential diagnostic pitfall. Diagnostic Pathology. 2008; 3:40.
  • Aljawad H, Al-Za’abi A.M, Sur M. Cyclin D1 positive lasma cell myeloma. Hematol Oncol Stem Cell Therapy. 2008; 1(1):68-70.
  • Niakosari F, Sur M. Agranular CD4+/CD56+ Hematodermic Neoplasm. A distinct entity described in the recent WHO-EORTC classification for Cutaneous Lymphomas. Archives of Pathology and Laboratory Medicine. 2007; 131: 149- 51.
  • Misir A, Sur M. Sertoliform Endometrioid Carcinoma of the Ovary: A potential diagnostic pitfall. Archives of Pathology and Laboratory Medicine. 2007; 131: 979- 81.
  • Sur M, AlArdati H, Ross C, Alowami S. TdT expression in Merkel cell carcinoma: potential diagnostic pitfall with blastic hematological malignancies and expanded immunohistochemical analysis. Modern Pathology. 2007;20: 1113- 20.
  • Sur M, Ross C, Moens F, Daya D. Intravascular Large B-cell Lymphoma of the Uterus: A Diagnostic Challenge. International Journal of Gynecological Pathology. 2005; 24: 201- 3.
  • Ursani N., Saleh R., Lytwyn A., Daya D., Ceballos C., Elit L., Sur M., Onuma K. Combined p53 and p16 expression is useful to distinguish between endometrial serous and endometriod carcinomas. Modern Pathology. 2009; 22(1): 239A.
  • Sur M, Kurian A, Ross C. Central Nervous System Lymphomas. A   Clinicopathologic Study. Modern Pathology. 2008; 21(1): 276A.
  • Pan L., Sussman J., Sur M., Elavathil L. Secondary malignancies amongst survivors of Hodgkin’s Lymphoma: An Institutional Review of the Current screening practices for breast cancer following thoracic irradiation. Radiotherapy and Oncology. 2007; 84 (suppl 2): S 47.
  • Sertoliform Endometrioid Carcinoma of the Ovary: Diagnosis and Prognosis. In: Methods of Cancer Diagnosis, Therapy and prognosis. MA. Hayat ed, Springer Company, Chapter 5, Book ID 189088; online version available (book chapter)
  • El Demellawy D, Sur M, Ross C, DeNardi F, Alowami S. Composite Multifocal Basal Cell carcinoma and Precursor B Lymphoblastic Leukemia: Case Report. Diagnostic Pathology. 2007; 2:32.
  • Sur M., Sur R.K., Cooper K., Levin V., Bizos D., Dubazana N. Morphologic Alterations in Esophageal Squamous Cell Carcinoma after Preoperative High Dose Rate Intraluminal Brachytherapy. Cancer. 1996; 77: 2200–2205.
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0